Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, March 14 '26)


 

    Ann Intern Med

  1. LALANI HS, DiResta R, Baron RJ, Scales D, et al
    Addressing Viral Medical Rumors and False or Misleading Information.
    Ann Intern Med. 2023 Jul 18. doi: 10.7326/M23-1218.
    PubMed         Abstract available


    Antimicrob Agents Chemother

  2. ZHENG X, You X, Liu Y, Wu B, et al
    Spatiotemporal dynamics and multiple driving factors of antimicrobial resistance in China during the COVID-19 pandemic (2019-2023): a provincial panel data analysis.
    Antimicrob Agents Chemother. 2026 Feb 9:e0160025. doi: 10.1128/aac.01600.
    PubMed         Abstract available


    Antiviral Res

  3. ZHANG T, Wang ZL, Li XY, Luo RH, et al
    Onvansertib and vilazodone inhibit SARS-CoV-2 replication via suppression of METTL3 RNA-m(6)A enzymatic activity.
    Antiviral Res. 2026 Feb 19:106376. doi: 10.1016/j.antiviral.2026.106376.
    PubMed         Abstract available

  4. YURGELONIS I, Rai DK, Li Z, Washington B, et al
    Analysis of Ibuzatrelvir's Activity Against SARS-CoV-2 Circulating Variants and In Vitro Resistance Mutations.
    Antiviral Res. 2026 Jan 30:106352. doi: 10.1016/j.antiviral.2026.106352.
    PubMed         Abstract available

  5. TOSELLI F, Jacobs S, Scheers E, Jacobs T, et al
    Optimal preclinical models for human dose projection of SARS-CoV-2 small molecule direct-acting antivirals.
    Antiviral Res. 2026 Feb 9:106363. doi: 10.1016/j.antiviral.2026.106363.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  6. DEO S, Desai K, Patare A, Wadapurkar R, et al
    Evaluation of self-amplifying mRNA platform for protein expression and genetic stability: Implication for mRNA therapies.
    Biochem Biophys Res Commun. 2023;680:108-118.
    PubMed         Abstract available


    Cell

  7. YU S, Lin Y, Li Y, Chen S, et al
    Systemic immune profiling of Omicron-infected subjects inoculated with different doses of inactivated virus vaccine.
    Cell. 2023;186:4615-4631.
    PubMed         Abstract available


    Epidemiol Infect

  8. FUNG IC, Liang H, Pierce KJ, Kraay ANM, et al
    Excess mortality in Mainland China after the end of the Zero COVID policy: A systematic review.
    Epidemiol Infect. 2026;154:e29.
    PubMed         Abstract available

  9. AKBARIAN S, Sheikhi M, Khedri P, Baharifar N, et al
    The correlation between humoral immune responses and severity of clinical symptoms in COVID-19 patients.
    Epidemiol Infect. 2023;151:e158.
    PubMed         Abstract available


    Eur J Epidemiol

  10. SLURINK IAL, de Boer AR, Bonten MJM, Sturkenboom MCJM, et al
    COVID-19 vaccination and short-term mortality risk: a nationwide self-controlled case series study in The Netherlands.
    Eur J Epidemiol. 2026;41:173-184.
    PubMed         Abstract available


    J Epidemiol Community Health

  11. BEVILACQUA L, Fox-Smith L, Lewins A, Jetha P, et al
    Impact of COVID-19 on the mental health of children and young people: an umbrella review.
    J Epidemiol Community Health. 2023;77:704-709.
    PubMed         Abstract available


    J Gen Virol

  12. NAZKI S, Tennakoon C, Reddy VRAP, Chen Y, et al
    Evaluating how infectious bursal disease virus (IBDV) infection influences influenza H3N8 challenge in chickens.
    J Gen Virol. 2026;107:002235.
    PubMed         Abstract available

  13. DISLERS A, Nilova O, Jansons J, Skrastina D, et al
    Immunogenicity of SARS-CoV-2 vaccine prototype based on virus-like particles of hepatitis B core antigen from genotype G and interleukin 12 expressing Semliki Forest virus as a genetic adjuvant.
    J Gen Virol. 2026;107:002240.
    PubMed         Abstract available


    J Infect

  14. ZHOU T, Zhang B, Zhang D, Jhaveri R, et al
    Pre-COVID-19 Body Mass Index and Postacute Cardiovascular, Gastrointestinal, and Neuropsychiatric Outcomes Among Children and Young Adults With SARS-CoV-2 Infection: An EHR-based Cohort Study from the RECOVER Initiative.
    J Infect. 2026 Feb 11:106702. doi: 10.1016/j.jinf.2026.106702.
    PubMed         Abstract available

  15. WANG Z, Dunican C, Dayananda P, Ingar S, et al
    Comparative cross-species transcriptomics during RSV infection identifies targets to treat RSV disease.
    J Infect. 2026;92:106696.
    PubMed         Abstract available


    J Virol

  16. FIELD CJ, Septer KM, Patel DR, Weaver VC, et al
    Defining the transmissible dose 50% for two pandemic influenza viruses in ferrets.
    J Virol. 2026 Mar 11:e0163525. doi: 10.1128/jvi.01635.
    PubMed         Abstract available

  17. HAN P, Meng Y, Zhang D, Xu Z, et al
    Structural basis of white-tailed deer, Odocoileus virginianus, ACE2 recognizing all the SARS-CoV-2 variants of concern with high affinity.
    J Virol. 2023 Sep 7:e0050523. doi: 10.1128/jvi.00505.
    PubMed         Abstract available


    JAMA

  18. WANG L, Nangle SJ, Waller-Pulido A, McMahan K, et al
    Vaccine-Elicited Antibody Responses to Influenza A(H3N2) Subclade K.
    JAMA. 2026 Mar 9:e262173. doi: 10.1001/jama.2026.2173.
    PubMed        

  19. JABAGI MJ, Bertrand M, Gabet A, Kolla E, et al
    Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus-Related Hospitalization in Newborns.
    JAMA. 2025 Dec 22:e2524082. doi: 10.1001/jama.2025.24082.
    PubMed         Abstract available


    Lancet

  20. NYBERG ST, Frank P, Ahmadi-Abhari S, Pentti J, et al
    Adult obesity and risk of severe infections: a multicohort study with global burden estimates.
    Lancet. 2026 Feb 9:S0140-6736(25)02474-2. doi: 10.1016/S0140-6736(25)02474.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  21. MALONEY P, Reeves EL, Wielgosz K, Price AM, et al
    Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026.
    MMWR Morb Mortal Wkly Rep. 2026;75:116-123.
    PubMed         Abstract available

  22. ZHU S, Quint J, Leon TM, Li NJ, et al
    Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - California, October 2025-January 2026.
    MMWR Morb Mortal Wkly Rep. 2026;75:124-128.
    PubMed         Abstract available


    N Engl J Med


  23. Current and Emerging Approaches to Evaluating Influenza Vaccine Performance.
    N Engl J Med. 2026;394:1144.
    PubMed        


    Pediatrics

  24. YAN AP, Archer NM, Arnold D, Hansbury E, et al
    Increasing COVID-19 Vaccination Rates for Children With Sickle Cell Disease.
    Pediatrics. 2023;152:e2022061011.
    PubMed         Abstract available


    PLoS Comput Biol

  25. LOPES R, Lan Y, Chitwood MH, Klaassen F, et al
    Quantifying the spatiotemporal dynamics of the first two epidemic waves of SARS-CoV-2 infections in the United States.
    PLoS Comput Biol. 2026;22:e1013983.
    PubMed         Abstract available


    PLoS Med

  26. KAMPITSI CE, Louro J, Mogensen H, Erdmann F, et al
    Childhood cancer in Sweden during the COVID-19 pandemic: Temporal patterns in incidence and survival in a nationwide register-based cohort study.
    PLoS Med. 2026;23:e1004934.
    PubMed         Abstract available


    PLoS One

  27. ALI MA, Sheikh H, Reza MS, Paul TR, et al
    Exploring potential phytocompounds from black cumin as drug molecules against SARS-CoV-2 infections through bioinformatics analysis.
    PLoS One. 2026;21:e0337970.
    PubMed         Abstract available

  28. CASTILLO-NAVARRETE JL, Bustos C, Guzman-Castillo A, Munoz-Reveco L, et al
    Development and validation of the BASE-66 inventory for comprehensive academic stress measurement.
    PLoS One. 2026;21:e0343308.
    PubMed         Abstract available

  29. SOGBESAN A, Bakare AA, Herzig van Wees S, Salako J, et al
    Exploring COVID-19 pandemic perceptions and vaccine uptake among community members and primary healthcare workers in Nigeria: A mixed methods study.
    PLoS One. 2026;21:e0310437.
    PubMed         Abstract available

  30. MESQUITA LO, Dos Santos DF, de Carvalho KMB
    Effect of COVID-19 on mortality due to diabetes mellitus in Brazil: A time series analysis from 2010 to 2023.
    PLoS One. 2026;21:e0344419.
    PubMed         Abstract available

  31. NELSON CE, Kauffman KD, Sakai S, Newbolt T, et al
    Glucocorticoids suppress early lung inflammation and impair control of SARS-CoV-2 in non-human primates.
    PLoS One. 2026;21:e0342849.
    PubMed         Abstract available

  32. DHOUIB W, Kacem M, Belghayeb O, Beji MO, et al
    Serological profile of naive patients affected by the first sars-cov-2 variant: A prospective study.
    PLoS One. 2026;21:e0344308.
    PubMed         Abstract available

  33. DUAH ASUMADU OK, Abiiro GA, Ndago JA, Kanligi DA, et al
    Prevalence and associated factors of health facility delivery during COVID-19 in the Tamale Metropolis of Ghana: Analytical cross-sectional study.
    PLoS One. 2026;21:e0344205.
    PubMed         Abstract available

  34. HU YZ, Qin ZL, Tang W, Hu ZL, et al
    Influence of COVID-19 on postoperative prognosis and pain management.
    PLoS One. 2026;21:e0344211.
    PubMed         Abstract available

  35. ANTUNES L, Nunes B, Nunez O, Martinez-Baz I, et al
    Modelling approaches for estimating vaccine effectiveness of consecutive SARS-CoV-2 variant sublineages in the absence of study-specific genetic sequencing data, VEBIS hospital network, Europe, 2023/24.
    PLoS One. 2026;21:e0343988.
    PubMed         Abstract available

  36. MYERS SP, Tsung C, Chen JC, Gokun Y, et al
    Factors correlated with financial hardship among cancer patients during the COVID-19 pandemic.
    PLoS One. 2026;21:e0342984.
    PubMed         Abstract available

  37. BAEK S, Cho H, Lee S, Yoo M, et al
    Integrated disease model considering mutation-induced infection waves with COVID-19 cases.
    PLoS One. 2026;21:e0341667.
    PubMed         Abstract available

  38. SULIMANY HGH, Almoataz E, Ali A, Faisal F, et al
    Moderating role of CEO expertise on the relationship between capital structure and financial reporting timeliness of Saudi-listed companies.
    PLoS One. 2026;21:e0338840.
    PubMed         Abstract available

  39. MAGALHAES JCN, Chiavegatto Filho ADP
    Predictive divergence in machine learning models for clinical mortality risk: A multicohort study of covid-19 patients.
    PLoS One. 2026;21:e0344354.
    PubMed         Abstract available

  40. BHANDARI B, Thapa P, Timilsina A, Karn RR, et al
    "It becomes more difficult when people don't empathize with us": COVID-19-related stigmatization experienced by survivors in Nepal.
    PLoS One. 2026;21:e0344123.
    PubMed         Abstract available

  41. ATAC O, Aydin V, Peterson LE, Waters TM, et al
    The impact of the COVID-19 pandemic on oral anticoagulation adherence in patients with atrial fibrillation managed in primary care: Results from the PRIME Registry.
    PLoS One. 2026;21:e0344020.
    PubMed         Abstract available

  42. BARTMANN C, Schmidt V, Morz M, Schwab M, et al
    Detection of spike protein in term placentas of COVID-19 vaccinated and/or SARS-CoV-2 infected women.
    PLoS One. 2026;21:e0344185.
    PubMed         Abstract available

  43. CORONADO ZK, Duke M, Rodriguez M, Avelar Portillo LJ, et al
    Latino/a experiences of homelessness in California: Qualitative findings from the California Statewide Study of People Experiencing Homelessness (CASPEH).
    PLoS One. 2026;21:e0344036.
    PubMed         Abstract available

  44. HAMROUNI M, Gupta A, Middleton S, Prosper S, et al
    The Nottingham recovery from COVID-19 research platform (NoRCoRP): Functional, clinical and patient-reported outcomes in adults referred to a post-COVID respiratory service.
    PLoS One. 2026;21:e0344210.
    PubMed         Abstract available

  45. WU C, Paradis NJ
    Near Neutral Selectionist Theories (NNST) for SARS-CoV-2 suggested by the substitution-mutation ratio (c/micro) analysis.
    PLoS One. 2026;21:e0343410.
    PubMed         Abstract available

  46. DIMNJAKOVIC J, Buble T, Poljicanin T, Brborovic H, et al
    Identifying high-risk combinations of metformin during COVID-19.
    PLoS One. 2026;21:e0343979.
    PubMed         Abstract available

  47. KIM TY, Min GJ, Cho SG, Kim S, et al
    Comprehensive analysis of mortality risk factors in low-grade B-cell lymphoma.
    PLoS One. 2026;21:e0328666.
    PubMed         Abstract available

  48. RICHARD L, Carter B, Liu M, Nisenbaum R, et al
    Acute healthcare utilization associated with positive SARS-CoV-2 testing or serology among people experiencing homelessness: A prospective cohort study.
    PLoS One. 2026;21:e0343639.
    PubMed         Abstract available

  49. KASULE J, Tonzel JL, Burns N, Hamby T, et al
    COVID-19 knowledge, attitudes, and practices among people vulnerable to HIV in Uganda: A cross-sectional cohort analysis.
    PLoS One. 2026;21:e0343507.
    PubMed         Abstract available

  50. ALOMARI HM, Bani Hani H, Alkhateeb T, Qutaishat D, et al
    Adoption and implementation of teleaudiology as a telehealth model in Jordan and Arab countries: A cross-sectional survey.
    PLoS One. 2026;21:e0343923.
    PubMed         Abstract available

  51. FROLKE SC, Amirkhan KG, van der Bom-Baylon N, van Gils M, et al
    Class switching toward IgG4 six months after primary mRNA-based COVID-19 vaccination in kidney patients.
    PLoS One. 2026;21:e0336320.
    PubMed         Abstract available

  52. CASSIM N, Coetzee LM, da Silva MP, Stevens WS, et al
    Using laboratory data to assess the impact of coronavirus (COVID-19) on reflex cryptococcal antigenaemia (CrAg) testing in South Africa.
    PLoS One. 2023;18:e0292062.
    PubMed         Abstract available

  53. STONEHAM CA, Singh R, De Leon A, Tafelmeyer P, et al
    A cluster of acidic residues in the cytoplasmic domain of SARS-CoV-2 Spike is required for virion-incorporation and infectivity.
    PLoS One. 2026;21:e0340644.
    PubMed         Abstract available

  54. MAZHAR L, Krebs N, Allen SI, Hobkirk AL, et al
    Enhancing recruitment and retention strategies in human tobacco research.
    PLoS One. 2026;21:e0340668.
    PubMed         Abstract available

  55. LAU HC, Sekawi Z, Ching SM, Abu Bakar N, et al
    Effectiveness of the influenza and Tdap vaccination educational module (InTroDuce-Programme) on knowledge and intention for antenatal vaccination: A cluster randomised controlled trial protocol among pregnant women in Malaysian primary care clinics.
    PLoS One. 2026;21:e0344651.
    PubMed         Abstract available

  56. PAN Y, Fan L, Goetz S
    Economic shocks, food insufficiency and mental health: Evidence from the COVID-19 pandemic.
    PLoS One. 2026;21:e0344745.
    PubMed         Abstract available

  57. JONES M, Reilly M, Simanek A, Stewart A, et al
    A randomized assessment of the impact of 'Those Nerdy Girls' newsletters on adult vaccination outcomes.
    PLoS One. 2026;21:e0344258.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  58. ESPINOZA B, Venkatramanan S, Scott Warren A, Lewis BL, et al
    Integrated framework to study genomic surveillance of selective sweeps in multivariants dynamics.
    Proc Natl Acad Sci U S A. 2026;123:e2521031123.
    PubMed         Abstract available

  59. FARAONE JN, Li P, Hong J, Zang J, et al
    Spike destabilization attenuates Mink Cluster 5 SARS-CoV-2.
    Proc Natl Acad Sci U S A. 2026;123:e2528367123.
    PubMed         Abstract available


    Vaccine

  60. MESLE MMI, Jorgensen P, Barakat A, Herring BL, et al
    Influenza vaccine recommendations and coverage (2018-2023): a foundation for pandemic preparedness and response.
    Vaccine. 2026;78:128391.
    PubMed         Abstract available

  61. MALLAH N, Pardo-Seco J, Rodriguez-Tenreiro-Sanchez C, Gine-Vazquez I, et al
    Methods and operational framework of GALFLU: Individually randomized pragmatic controlled trial of high- versus standard-dose influenza vaccination in older adults.
    Vaccine. 2026;79:128435.
    PubMed         Abstract available

  62. NUSSBAUM J, Cao X, Railkar RA, Sachs JR, et al
    Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults.
    Vaccine. 2023;41:6488-6501.
    PubMed         Abstract available

  63. MATHUR I, Church R, Ruisch A, Noyes K, et al
    Insights to COVID-19 vaccine delivery: Results from a survey of 27 countries.
    Vaccine. 2023;41:6406-6410.
    PubMed         Abstract available

  64. YESKENDIR A, Gusmanov A, Zhussupov B
    Parental attitudes, beliefs and behaviors toward childhood and COVID-19 vaccines: A countrywide survey conducted in Kazakhstan examining vaccine refusal and hesitancy.
    Vaccine. 2023;41:6548-6557.
    PubMed         Abstract available

  65. DA PENHA GOMES GOUVEA M, Lira Machado KLL, de Oliveira YGP, Moulaz IR, et al
    Timeline kinetics of protective immunity to SARS-CoV-2 upon primary vaccination and humoral response to variants after booster dose.
    Vaccine. 2023;41:6514-6528.
    PubMed         Abstract available

  66. JACOBS ET, Cordova-Marks FM, Farland LV, Ernst KC, et al
    Understanding low COVID-19 booster uptake among US adults.
    Vaccine. 2023;41:6221-6226.
    PubMed         Abstract available

  67. YASUGI M, Nakagama Y, Kaku N, Nitahara Y, et al
    Characteristics of epitope dominance pattern and cross-variant neutralisation in 16 SARS-CoV-2 mRNA vaccine sera.
    Vaccine. 2023;41:6248-6254.
    PubMed         Abstract available

  68. VAUX S, Gautier A, Nassany O, Bonmarin I, et al
    Vaccination acceptability in the French general population and related determinants, 2000-2021.
    Vaccine. 2023;41:6281-6290.
    PubMed         Abstract available

  69. MEERAUS W, Stuurman AL, Durukal I, Conde-Sousa E, et al
    COVID-19 vaccine booster doses provide increased protection against COVID-19 hospitalization compared with previously vaccinated individuals: Interim findings from the REFORCO-Brazil real-world effectiveness study during Delta and Omicron.
    Vaccine. 2023;41:6366-6378.
    PubMed         Abstract available

  70. JI WY, Liu DL, Yu R, Miao L, et al
    Vaccination coverage survey of children aged 1-3 years in Beijing, China, 2005-2021.
    Vaccine. 2023;41:6444-6452.
    PubMed         Abstract available

  71. LASSAUNIERE R, Polacek C, Linnea Tingstedt J, Fomsgaard A, et al
    Preclinical evaluation of a SARS-CoV-2 variant B.1.351-based candidate DNA vaccine.
    Vaccine. 2023;41:6505-6513.
    PubMed         Abstract available

  72. JALALIZADEH M, Leme PAF, Buosi K, Dionato FAV, et al
    Healthcare Workers (HCWs) and non-HCWs reaction to Bacillus Calmette-Guerin (BCG) in the BATTLE trial.
    Vaccine. 2023;41:6599-6606.
    PubMed         Abstract available


    Virology

  73. ORTEGA GRANDA O, Alvarez K, Mate-Perez MJ, Canard B, et al
    Macro1 domain residue F156: A hallmark of SARS-CoV-2 de-MARylation specificity.
    Virology. 2023;587:109845.
    PubMed         Abstract available

  74. HAKIM MS, Widyaningsih SA, Ikram A, Goeijenbier M, et al
    Fundamental concepts of convergent (parallel) evolution in human-pathogenic viruses and their implications for global health.
    Virology. 2026;618:110854.
    PubMed         Abstract available

  75. KIM IH, No JS, Kim JA, Park AK, et al
    Genomic epidemiology of SARS-CoV-2 variants in South Korea between January 2020 and February 2023.
    Virology. 2023;587:109869.
    PubMed         Abstract available

  76. KNANY HR, Elsabbagh SA, Shehata MA, Eldehna WM, et al
    In silico screening of SARS-CoV2 helicase using African natural products: Docking and molecular dynamics approaches.
    Virology. 2023;587:109863.
    PubMed         Abstract available

  77. SHIAU AL, Lee KH, Cho HY, Chuang TH, et al
    Molnupiravir, a ribonucleoside antiviral prodrug against SARS-CoV-2, alters the voltage-gated sodium current and causes adverse events.
    Virology. 2023;587:109865.
    PubMed         Abstract available

  78. PONDE RAA
    Physicochemical effects of emerging exchanges on the spike protein's RBM of the SARS-CoV-2 Omicron subvariants BA.1-BA.5 and its influence on the biological properties and attributes developed by these subvariants.
    Virology. 2023;587:109850.
    PubMed         Abstract available


    Virus Res

  79. BONIARDI I, Corona A, Basquin J, Basquin C, et al
    Suramin inhibits SARS-CoV-2 nucleocapsid phosphoprotein genome packaging function.
    Virus Res. 2023;336:199221.
    PubMed         Abstract available

Comments

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...